

STRICTLY CONFIDENTIAL AND NOT FOR DISTRIBUTION

TRIVARIATE RESEARCH

HAVE YOU LOOKED AT STOCKS WITH CONVERTIBLE BONDS?

ADAM S. PARKER, Ph.D., FOUNDER

adam@trivariateresearch.com
646-734-7070

CHANG GE, ANALYST

chang@trivariateresearch.com
614-397-0038

MAXWELL ARNOLD, ANALYST

maxwell@trivariateresearch.com
347-514-1234

RYAN MCGOVERN, DIR. OF RESEARCH SALES

ryan@trivariateresearch.com
973-271-8017

COLIN COONEY, HEAD OF SALES

colin@trivariateresearch.com
617-910-7934

RESEARCH SUMMARY AND INVESTMENT CONCLUSIONS

Background: We looked at the US equity market and found that over the long term between 1500 and 1750 of the top 3000 stocks have longer-term debt. Within that group, about 20% of companies also issue convertible bonds. The prevalence of convertibles has declined steadily since 2010, recovered briefly from 2018 through the post-Covid period, and has been drifting lower again in recent years. The average company with any debt has 3x more “regular” than convertible debt.

Lower yield and shorter maturity than other bonds: Convertible bonds have consistently carried an average of 150-200 bps lower coupon rate than the broader bond market. Both segments saw coupons decline through the 2010s, bottom in 2021, and modestly rise since. Maturities remain shorter for convertibles, averaging 2.6-years today versus 4.5 years for the broader bond market. Notably, in the past two years median maturities on convertibles have ticked higher, indicating a pickup in new issuance relative to straight bonds, where maturities have shortened.

New convertible issuance: Convertible activity historically was cyclical, rising during favorable market conditions. From 2010 to 2018, quarterly issuance generally ranged between 20 and 40 offerings, before surging in 2020-21 when equity markets were strong and financing costs were low. Issuance volumes peaked at close to 90 deals in a single quarter during this period. The pickup in 2024 and early 2025 suggests that the convertible bond market remains an active channel for funding, even as broader bond issuance has slowed.

Convertibles by cohort: Convertible issuance is more common among smaller companies, with micro- and small-caps using converts far more than large or mega-caps. **Growth stocks are also more frequent issuers than value stocks.** Junk stocks tend to utilize convertibles more often than high-quality companies. By sector, **Technology and Healthcare use converts the most, with over 40% of bond issuers also issuing convertibles.** In contrast, in Financials, Real Estate, Materials, and Industrials companies are currently making relative less use of the convertible bond market.

INVESTMENT CONCLUSIONS

Returns: The stock returns of companies with convertible bonds are **increasingly more volatile** than the stocks of companies with straight bonds. This could partly be due to these companies having higher debt-to-equity ratios. Over the last 15 years, companies with convertible bonds in the Materials sector, despite the lower number of issuances, have performed best, and those in Communication Services, Consumer Staples, and Consumer Discretionary the worst. Value companies have on average outperformed growth companies in the convertible space, which is the opposite of the overall market for companies with no bonds.

FCF and net margins: Stocks with convertible bonds had the same free cash flow yield as stocks with straight debt in 2010. Today however, the median stock with a convertible bond has 1.3% lower free cash flow yield than those that don't have converts. The median stock with a convert has nearly 600bps lower net margins than those without a convert.

Short interest and beta of stocks with convertible bonds are unsurprisingly therefore higher.


Converts work in a risk on regime: US equities with convertibles tend to beat their industry average when the S&P500 is up. They materially lag when financial conditions are tightening.

Within the growth stock universe, convertible issuers with lower debt-to-equity ratios have sharply underperformed those with higher leverage, the opposite of how leverage works among value stocks with converts.


Long and short ideas: Slide 13 shows long and short ideas among stocks with convertibles, based on earnings growth and leverage, which were effective signals for stock selection. Buy ideas include Cloudflare, Alnylam Pharmaceuticals, MP Materials, and Lumentum. Among the short ideas are issuers with downward revisions and below-average debt, including ON Semiconductor, Lucid, Oscar Health, and Lantheus.

ABOUT 20% OF STOCKS THAT ISSUE BONDS ISSUE CONVERTS

We looked at the US equity market and found fairly consistently 1500-1750 of the top 3000 stocks have longer-term debt i.e. bonds or notes (left). This base of issuers has remained broadly stable for more than a decade. Within that group, about 20% also issue convertible bonds. The prevalence of convertibles has declined steadily since 2010, recovered briefly from 2018 through the post-Covid period, and has been drifting lower again in recent years (right).




Source: Trivariate Research




Source: Trivariate Research

THE AVG. CO. HAS 3X MORE “REGULAR” THAN CONVERTIBLE DEBT

For convertible issuers, the share of debt in convertible bonds has fluctuated sharply. The level was below 20% through most of the 2010s, surged to more than 35% around 2020–21 as firms tapped strong equity markets, and is 24% at present (left). Nearly all convertible bonds of US companies are issued in USD, highlighting their domestic focus. In contrast, the broader bond universe has steadily diversified, with the share of issuers funding solely in USD falling from about 95% in 2010 to under 90% today.




Source: Trivariate Research




Source: Trivariate Research

CONVERTIBLE BONDS HAVE 150BPS LOWER COUPONS TODAY

Convertible bonds have consistently carried lower coupon rates than the broader bond market, 150–200 bps on average (left). Both segments saw coupons decline through the 2010s, bottoming in 2021, with a modest rise since then. Maturities remain shorter for convertibles, averaging 2.6 years today versus 4.5 years for the broader bond market (right). Notably, in the past two years median maturities on convertibles have ticked higher, indicating a pickup in new issuance relative to straight bonds, where maturities have shortened.



Source: Trivariate Research




Source: Trivariate Research

THERE WERE 40 CONVERTIBLE BOND DEALS IN Q2 2025

New convertible issuance has historically been cyclical, with activity rising in waves during favorable market conditions. From 2010 to 2018, quarterly issuance generally ranged between 20 and 40 deals, before surging in 2020-21 when equity markets were strong and financing costs were low. Issuance volumes peaked at close to 90 deals in a single quarter during this period. More recently, activity has normalized to a steadier pace of 30-50 deals per quarter. The pickup in 2024 and early 2025 suggests that the convertible bond market remains an active channel for funding, even as broader bond issuance has slowed.


Number of New Convertible Issuance Per Quarter
Through 2025 Q2



Source: Trivariate Research

TECH. AND HEALTHCARE COMPANIES USE CONVERTS THE MOST


Convertible issuance is more common among smaller companies, with micro- and small-caps using the market far more than large or mega-caps. Growth stocks are also more frequent issuers than value. Junk stocks tend to turn to convertibles more often than high-quality companies. By sector, Technology and Healthcare use converts the most, with over 40% of bond issuers also issuing convertibles. In contrast, in Financials, Real Estate, Materials, and Industrials companies are currently making relatively less use of the convertible bond market.




Source: Trivariate Research

STOCKS WITH CONVERTS ARE MORE VOLATILE THAN THOSE WITHOUT

The stock returns of companies with convertible bonds are increasingly relatively more volatile than the stocks of companies with straight bonds (left). This may in part be because these companies are likely to have higher debt-to-equity (right). The average company with a convertible bond has 3% higher debt-to-equity than the average company in its industry, whereas those with straight debt have identical leverage.





Source: Trivariate Research



Source: Trivariate Research



MARGINS AND FCF ARE WORSE FOR STOCKS WITH CONVERTS

Stocks with convertible bonds had the same free cash flow yield as stocks with straight debt in 2010. Today however, the median stock with a convertible bond has 1.3% lower free cash flow yield than those that don't have converts (left). Net margins for stocks with converts have relatively eroded over time, such that the median stock with a convert has nearly 600bps lower net margins than those without a convert (right).




BETA AND SHORT INTEREST HAS ALSO RELATIVELY INCREASED

Unsurprisingly, given the inferior margins and FCF characteristics, the median short interest has risen for stocks with converts and is now over 4% higher than the industry average. It makes sense that there would be higher short interest structurally, given many investors buy the convert and short the stock to clip the coupon, but it is less obvious that the short interest should have relatively increased this much (left). It is likely illustrative of an increasingly inferior group of attributes for stocks with converts than straight debt. The beta of the median stock with a convert is also now relatively higher than it used to be (right).



VALUE BEATS GROWTH, MATERIALS BETTER THAN CONSUMER


We evaluated the returns of stocks with convertible bonds. Over the last 15 years, companies with convertible bonds in the Materials sector, despite the lower number of issuances, have performed best, and those in Communication Services, Consumer Staples, and Consumer Discretionary the worst. Value companies have on average outperformed growth companies in the convertible space.




Source: Trivariate Research

A DOWN MARKET OR TIGHTER FINANCIAL CONDITIONS ARE BAD

Despite the difference between US stocks with converts or just straight debt, the stocks have generally been highly correlated, always averaging above 0.7 (left) over a 6-month period. Correlations declined only during fears about big changes to interest rates. US equities with convertibles tend to beat their industry average when the S&P500 is up. They materially lag when the market is down, and when financial conditions are tightening (right).




Source: Trivariate Research




Source: Trivariate Research

CONVERTIBLE BOND ISSUERS ARE CORRELATED TO R2K AND QQQ

Convertible issuers move broadly in line with equity benchmarks, but with some differences relative to non-convert issuers. Against the Russell 2000, correlations for both groups typically hold above 90%, with only brief declines in stress periods. Against the Nasdaq, however, convert issuers now show higher correlations than non-converts, reflecting their greater concentration in growth-oriented sectors (left). Most recently, correlations for both groups have been high returning toward historical averages (right).




Source: Trivariate Research




Source: Trivariate Research

EARNINGS REVISIONS WORK, EARNINGS GROWTH USED TO

For convertible issuers, earnings revisions are effective at identifying winners from losers (left). Stocks with the most positive earnings estimate revisions have steadily outperformed those with the weakest revisions, producing sustained cumulative gains over the past decade. A similar pattern holds for forward EPS growth, where high-growth issuers delivered large excess returns through 2021-22 before giving back a huge part of those gains in the recent years (right). Our judgment is change in earnings expectations, not the level of expectations will matter for security selection.



Source: Trivariate Research




Source: Trivariate Research

HIGH DEBT WORKS IN GROWTH, BUT NOT IN VALUE

Within the growth stock universe, convertible issuers with lower debt-to-equity ratios have sharply underperformed those with higher leverage (left) which is not the case for value universe (right). This runs counter to the usual expectation that balance sheet strength is rewarded and suggests that for growth convertible issuers, the market has favored firms willing to take on debt to finance expansion, or that those stocks have outperformed because their other fundamentals, like growth and margin, have been good enough to offset their incremental indebtedness.



Source: Trivariate Research



Source: Trivariate Research

LONG AND SHORT IDEAS AMONG STOCKS WITH CONVERTIBLE BONDS

The screens below highlight two sets of growth convertible issuers. On the long side (left) are companies with upward earnings revisions and above-average debt, including names such as Cloudflare, Alnylam Pharmaceuticals, MP Materials, and Lumentum. On the short side (right) are issuers with downward revisions and below-average debt, including ON Semiconductor, Lucid, Oscar Health, and Lantheus.

| Long Ideas Growth Convertible Issuers with Up Revision and Above Average Debt As of End-August, 2025 | | | | |
|--|---|------------------------|----------------------------|--------------------------------|
| Ticker | Company | Sector | Market Cap. (US\$ Bil.) | Convertible Debt Percentage |
| NET | Cloudflare, Inc. | Information Technology | 72.73 | 94% |
| ALNY | Alnylam Pharmaceuticals, Inc. | Health Care | 58.53 | 37% |
| MP | MP Materials Corp. | Materials | 12.60 | 96% |
| LITE | Lumentum Holdings Inc. | Information Technology | 9.28 | 96% |
| IRTC | iRhythm Technologies, Inc. | Health Care | 5.46 | 88% |
| ALHC | Alignment Healthcare, Inc. | Health Care | 3.24 | 98% |
| ATEC | Alphatec Holdings, Inc. | Health Care | 2.35 | 58% |
| FIVN | Five9, Inc. | Information Technology | 2.08 | 92% |
| ANIP | ANI Pharmaceuticals, Inc. | Health Care | 1.88 | 49% |
| PACB | Pacific Biosciences of California, Inc. | Health Care | 0.39 | 93% |

Source: Trivariate Research

| Short Ideas Growth Convertible Issuers with Down Revision and Below Average Debt As of End-August, 2025 | | | | |
|---|-------------------------------|------------------------|----------------------------|--------------------------------|
| Ticker | Company | Sector | Market Cap. (US\$ Bil.) | Convertible Debt Percentage |
| ON | ON Semiconductor Corporation | Information Technology | 20.28 | 63% |
| LCID | Lucid Group, Inc. | Consumer Discretionary | 6.08 | 74% |
| OSCR | Oscar Health, Inc. | Financials | 4.30 | 84% |
| LNTH | Lantheus Holdings, Inc. | Health Care | 3.73 | 93% |
| PAR | PAR Technology Corporation | Information Technology | 2.08 | 99% |
| AAOI | Applied Optoelectronics, Inc. | Information Technology | 1.51 | 60% |
| IE | Ivanhoe Electric Inc. | Materials | 1.18 | 42% |
| ATAI | Atai Life Sciences N.V. | Health Care | 0.98 | 52% |
| INDI | indie Semiconductor, Inc. | Information Technology | 0.90 | 91% |

Source: Trivariate Research

DISCLOSURES

Disclaimer

This presentation is confidential and may not be reproduced or distributed without the express prior written permission of Trivariate Research LP and its affiliates (collectively, “Trivariate”).

The information contained herein reflects the opinions and projections of Trivariate as the date of publication, which are subject to change without notice at any time subsequent to the date of issue. Trivariate does not represent that any opinion or projection expressed herein will be realized. All information provided is for informational and research purposes only and should not be deemed as investment advice or a recommendation to purchase or sell any specific portfolio investment, security or other asset. While the information presented herein is believed to be reliable, no representation or warranty is made concerning the accuracy of any data or other information presented. Information obtained by Trivariate from third party sources in connection with the preparation of this presentation has not been independently verified by Trivariate. Additional information regarding Trivariate is available on request.

Any projections, forecasts, targets or other estimates presented herein constitute “forward-looking statements” that can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “forecasted,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” or the negatives thereof or other variations thereon or comparable terminology. Furthermore, any projections, targets, forecasts or other estimates in this presentation are “forward-looking statements” and are based upon certain assumptions that may change. Due to various risks and uncertainties, actual events or results or the actual performance of the funds may differ materially from those reflected or contemplated in such forward-looking statements. Moreover, actual events are difficult to predict and often depend upon factors that are beyond the control of the Trivariate. Nothing herein shall under any circumstances create an implication that the information contained herein is correct as of any time after the earlier of the relevant date specified herein or the date of this presentation. In addition, unless the context otherwise requires, the words “include,” “includes,” “including” and other words of similar import are meant to be illustrative rather than restrictive. Forward-looking statements and discussions of the business environment included herein (e.g., With respect to financial markets, business opportunities, demand, investment pipeline and other conditions) are subject to the ongoing novel coronavirus outbreak (“COVID” or “COVID-19”). The full impact of COVID-19 is particularly uncertain and difficult to predict, therefore such forward-looking statements do not reflect its ultimate potential.

This shall not constitute an offer to sell or the solicitation of an offer to buy any interests in any fund, product or account that is or may in the future be advised or managed by, Trivariate or any of its affiliates.

All data sourced from S&P Global, Bloomberg, or our Trivariate estimates. All forward-looking-statements reflect the opinion of Trivariate.